On December 2, 2019 Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, reported that its Chief Executive Officer Doug Manion, MD, will present at the Piper Jaffray 31st Annual Healthcare Conference, to be held December 3-5 at the Lotte New York Palace in New York (Press release, Kleo Pharmaceuticals, DEC 2, 2019, View Source [SID1234551849]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During his presentation, Dr. Manion will provide an overview of Kleo’s development strategy for its pipeline of small molecule and synthetic peptide compounds that function similar to highly complex biologics, while offering multiple potential advantages. The overview will also outline Kleo’s key value drivers including its proprietary technology platforms that drive in-house drug development and partnership opportunities, the multiple in-house and collaborative channels through which it is building its immuno-oncology pipeline and its discovery collaboration with PeptiDream. Human studies are anticipated in 2020 for Kleo’s first product candidate to move into the clinic, CD38-ARM, a CD38 targeting antibody recruiting molecule (ARM) to treat multiple myeloma.

Dr. Manion will also discuss another platform technology at Kleo, which uses site-directed, chemical conjugation of off-the-shelf antibodies to enhance or add functionality. Monoclonal antibody therapy enhancers (MATEs) offer a number of opportunities to optimize or repurpose biologics currently in development.

Details of the presentations are as follows:

Event:

31st Annual Piper Jaffray Conference

Date:

December 3

Time:

2:10-2:30 p.m. EST

Location:

Lotte New York Palace, New York

Room:

Harlem Track – Kennedy 2, 4th Floor

On December 2, 2019 NantKwest presented the corporate presentation (Presentation, NantKwest, DEC 2, 2019, https://nantkwest.com/wp-content/uploads/2019/12/NantKwest%20KOL%20December%202019%20Presentation.pdf [SID1234551874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 2, 2019 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019 (Press release, Eli Lilly, DEC 2, 2019, https://investor.lilly.com/news-releases/news-release-details/lilly-participate-evercore-isi-2nd-annual-healthconx-conference [SID1234551818]). Daniel Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:30 a.m., Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On December 2, 2019 Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, reported that Paul Rennert, Ph.D., President and Chief Scientific Officer, will deliver an oral presentation at the 61st ASH (Free ASH Whitepaper) Annual Meeting & Exposition, December 7 – 10, 2019, Orange County Convention Center, Orlando, FL (Press release, Aleta Biotherapeutics, DEC 2, 2019, View Source [SID1234551834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The 61st ASH (Free ASH Whitepaper) Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD19-anti-CD20 bridging protein technology," said Paul Rennert, Ph.D., President and Chief Scientific Officer of Aleta Biotherapeutics. "We look forward to advancing the development of this novel therapy based on the data we will be presenting on December 7."

Oral Presentation Details
Title: 252 A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment in vivo
Session Name: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Mechanisms
Presenter: Paul Rennert, Ph.D.
Session Date: Saturday, December 7, 2019
Session Time: 2:00 PM – 3:30 PM
Presentation Time: 3:15 PM
Location: Orange County Convention Center, Valencia A (W415A)

On December 2, 2019 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in a fire-side chat with the analyst at the Evercore ISI 2nd Annual HealthCONx Conference in Boston, MA on Tuesday, December 3, 2019, at 4:15 p.m. ET (Press release, MacroGenics, DEC 2, 2019, http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-participate-evercore-isi-healthconx-conference [SID1234553171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fire-side chat may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of the webcast on its website for 30 days after the conference.